|
Your best online resource for Diabetes and - Blood Sugar Level ... Blood Sugar Level: Diabetes or Diabeties Library - Diabetes Blood Sugar ...
|
Study of 24 Hour Blood Pressure and the Association to Complications to Type 1 Diabetes
<b>Conditions</b>: Type 1 Diabetes; Hypertension<br/><b>Intervention</b>: <br/><b>Sponsor</b>: Steno Diabetes Center<br/><b>Recruiting</b> - verified April 2010
A Study on the Prevalence of Obstructive Sleep Apnea in Patients With Type II Diabetes Mellitus
<b>Conditions</b>: Obstructive Sleep Apnea; Diabetes Mellitus<br/><b>Intervention</b>: <br/><b>Sponsor</b>: The University of Hong Kong<br/><b>Completed</b> - verified July 2010
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
<b>Condition</b>: Diabetic Macular Edema<br/><b>Interventions</b>: Drug: Ranibizumab; Drug: ranibizumab; Drug: ranibizumab<br/><b>Sponsor</b>: Novartis Pharmaceuticals<br/><b>Not yet recruiting</b> - verified July 2010
To Evaluate if Wide Glucose Fluctuations Lead to Injury of Heart Nerves
<b>Condition</b>: Type 1 Diabetes Mellitus<br/><b>Intervention</b>: <br/><b>Sponsor</b>: University of Michigan<br/><b>Recruiting</b> - verified May 2010
Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part I)
<b>Conditions</b>: Vascular Diseases; Diabetes<br/><b>Interventions</b>: Device: femoral-popliteal bypass; Device: stent<br/><b>Sponsors</b>: Peking Union Medical College Hospital; Beijing Tongren Hospital; Xuanwu Hospital, Beijing<br/><b>Not yet recruiting</b> - verified July 2010
Comparing Safety and Efficacy of NN5401 With Insulin Glargine in Subjects With Type 2 Diabetes: An Extension to Trial NN5401-3590
<b>Condition</b>: Diabetes Mellitus, Type 2<br/><b>Interventions</b>: Drug: NN5401; Drug: insulin glargine<br/><b>Sponsor</b>: Novo Nordisk<br/><b>Recruiting</b> - verified July 2010
Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin
<b>Condition</b>: Type 2 Diabetes Mellitus<br/><b>Interventions</b>: Drug: LIXISENATIDE (AVE0010); Drug: Placebo<br/><b>Sponsor</b>: Sanofi-Aventis<br/><b>Recruiting</b> - verified July 2010
Does Vitamin D Reduce Risk of Developing Type II DM in High Risk Individuals
<b>Condition</b>: Type 2 Diabetes Mellitus<br/><b>Interventions</b>: Drug: Vitamin D3; Drug: Placebo<br/><b>Sponsor</b>: King Faisal Specialist Hospital & Research Center<br/><b>Not yet recruiting</b> - verified July 2010
Does Vitamin D Improve Glycemic Control in Type II DM?
<b>Conditions</b>: Diabetes Mellitus; Vitamin D Deficiency<br/><b>Interventions</b>: Drug: vitamin D3 2000 IU; Drug: vitamin D3 5000 IU; Drug: Placebo<br/><b>Sponsor</b>: King Faisal Specialist Hospital & Research Center<br/><b>Not yet recruiting</b> - verified July 2010
Insulin Dosage Software Program for People With Type 1 and Type 2 Diabetes
<b>Conditions</b>: Diabetes; Insulin<br/><b>Intervention</b>: Device: insulin dose software<br/><b>Sponsors</b>: Park Nicollet Institute; National Institutes of Health (NIH); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Hygieia, Inc; International Diabetes Center at Park Nicollet<br/><b>Recruiting</b> - verified June 2010
Type 2 Diabetes and Obesity in Mexican Pimas: Gene-Environment Interaction
<b>Condition</b>: Type 2 Diabetes Mellitus<br/><b>Intervention</b>: <br/><b>Sponsor</b>: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)<br/><b>Recruiting</b> - verified June 2010
Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus
<b>Condition</b>: Diabetes Mellitus, Type 2<br/><b>Intervention</b>: Drug: Insulin Glargine<br/><b>Sponsor</b>: Sanofi-Aventis<br/><b>Not yet recruiting</b> - verified July 2010
A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy
<b>Condition</b>: Type 2 Diabetes<br/><b>Interventions</b>: Drug: SK-0403; Drug: Placebo; Drug: Sitagliptin<br/><b>Sponsor</b>: Kowa Research Institute, Inc.<br/><b>Not yet recruiting</b> - verified June 2010
Tu Salud Si Cuenta: UT Community Outreach Program for Community-based Diabetes Prevention and Control.
<b>Condition</b>: Diabetes, Obesity<br/><b>Intervention</b>: Behavioral: Tu Salud Si Cuenta Behavioral Intervention<br/><b>Sponsor</b>: The University of Texas Health Science Center, Houston<br/><b>Recruiting</b> - verified July 2010
Hypothalamic Function Before and After Bariatric Surgery
<b>Conditions</b>: Obesity; Diabetes<br/><b>Interventions</b>: Procedure: Roux en Y gastric bypass and lap. gastric banding; Behavioral: Prodimed dietary intervention<br/><b>Sponsor</b>: Leiden University Medical Center<br/><b>Recruiting</b> - verified January 2010
Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema
<b>Conditions</b>: Diabetic Retinopathy; Diabetic Macular Edema<br/><b>Intervention</b>: <br/><b>Sponsor</b>: National Eye Institute (NEI)<br/><b>Recruiting</b> - verified July 2010
Psoriasis Inflammation and Systemic Co Morbidities
<b>Condition</b>: Psoriasis<br/><b>Intervention</b>: <br/><b>Sponsors</b>: Rockefeller University; Weill Medical College of Cornell University<br/><b>Recruiting</b> - verified July 2010
The Effectiveness of Lubiprostone in Constipated Diabetics
<b>Conditions</b>: Constipation; Diabetes; Colon Transit<br/><b>Intervention</b>: Drug: Lubiprostone<br/><b>Sponsor</b>: Emory University<br/><b>Not yet recruiting</b> - verified July 2010
Noninvasive Transcutaneous Glucometer Development
<b>Conditions</b>: Healthy; Prediabetic State (IGT); Diabetes Mellitus, Type 2; Diabetes Mellitus, Type 1<br/><b>Intervention</b>: <br/><b>Sponsor</b>: InLight Solutions<br/><b>Completed</b> - verified February 2008
Left Atrial Distensibility to Predict Left Ventricular Filling Pressure and Prognosis in Patients With Severe Mitral Regurgitation
<b>Conditions</b>: Mitral Valve Insufficiency; Atrial Fibrillation; Heart Failure<br/><b>Intervention</b>: Procedure: Cardiac catheterization<br/><b>Sponsors</b>: Kaohsiung Veterans General Hospital.; National Science Council, Taiwan<br/><b>Recruiting</b> - verified June 2010
Comprehensive Analyses of Multidetector-row Cardiac Computed Tomography Data in Koreans
<b>Condition</b>: Coronary Disease<br/><b>Intervention</b>: <br/><b>Sponsors</b>: Seoul National University Bundang Hospital; The Korean Society of Lipidology and Atherosclerosis<br/><b>Recruiting</b> - verified June 2010
Effect of Recombinant Human Growth Hormone (rhGH) Administration on Visceral Adiposity and Markers of Cardiovascular Risk in Obese Adolescent Girls
<b>Condition</b>: Obesity<br/><b>Interventions</b>: Drug: recombinant human growth hormone (rhGH); Drug: Placebo<br/><b>Sponsors</b>: Massachusetts General Hospital; Genentech<br/><b>Recruiting</b> - verified July 2010
Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)
<b>Condition</b>: Type 2 Diabetes Mellitus<br/><b>Intervention</b>: Drug: Dapagliflozin<br/><b>Sponsor</b>: Bristol-Myers Squibb<br/><b>Not yet recruiting</b> - verified July 2010
Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease.
<b>Condition</b>: Diabetes Mellitus<br/><b>Intervention</b>: Drug: Glucobay (Acarbose, BAYG5421)<br/><b>Sponsor</b>: Bayer<br/><b>Completed</b> - verified July 2010
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
<b>Condition</b>: Diabetes Mellitus, Type 2<br/><b>Interventions</b>: Drug: insulin aspart; Drug: insulin detemir; Drug: insulin aspart; Drug: insulin detemir<br/><b>Sponsor</b>: Novo Nordisk<br/><b>Not yet recruiting</b> - verified July 2010
Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans
<b>Condition</b>: Type II Diabetes Mellitus<br/><b>Intervention</b>: <br/><b>Sponsors</b>: Arizona State University; Takeda Pharmaceuticals North America, Inc.<br/><b>Recruiting</b> - verified July 2010
Vitamin D in Vulnerable Adults
<b>Conditions</b>: Frail Elderly; Vitamin D Deficiency<br/><b>Interventions</b>: Dietary Supplement: vitamin D; Dietary Supplement: placebo<br/><b>Sponsor</b>: Department of Veterans Affairs<br/><b>Not yet recruiting</b> - verified July 2010
Left Atrial Distensibility and Left Ventricular Filling Pressure in Acute Myocardial Infarction
<b>Condition</b>: Myocardial Infarction<br/><b>Intervention</b>: Procedure: Primary percutaneous coronary intervention<br/><b>Sponsors</b>: Kaohsiung Veterans General Hospital.; No other funding source in this study<br/><b>Completed</b> - verified December 2007
Use of Bevacizumab in Trabeculectomy Surgery
<b>Conditions</b>: Glaucoma; Optic Neuropathy; Fibrosis<br/><b>Interventions</b>: Drug: Bevacizumab; Drug: Control<br/><b>Sponsors</b>: Sunnybrook Health Sciences Centre; Glaucoma Research Society of Canada<br/><b>Recruiting</b> - verified July 2010
Safety and Efficacy Study Comparing 3 New Types of Coronary Stents
<b>Conditions</b>: Coronary Artery Disease; Stents; Coronary Thrombosis<br/><b>Interventions</b>: Device: coronary stent placement; Device: Coronary stent placement; Device: coronary stent placement<br/><b>Sponsor</b>: University Hospital, Basel, Switzerland<br/><b>Recruiting</b> - verified July 2010
Establishment of Biomarkers for Fabry Disease
<b>Condition</b>: Fabry Disease<br/><b>Intervention</b>: Other: Fluorescein angiography<br/><b>Sponsors</b>: Ohio State University; Genzyme<br/><b>Not yet recruiting</b> - verified July 2010
The Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) Study
<b>Conditions</b>: Infant; Obesity<br/><b>Interventions</b>: Behavioral: Child Safety Insights; Behavioral: Child Feeding Insights<br/><b>Sponsors</b>: Penn State University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)<br/><b>Not yet recruiting</b> - verified July 2010
Anticholinergic vs. Botox Comparison Study
<b>Conditions</b>: Urge Urinary Incontinence; Overactive Bladder Syndrome<br/><b>Interventions</b>: Drug: Botulinum toxin A (Botox A®); Drug: Solifenacin 5mg; Drug: Solifenacin 10mg; Drug: Trospium chloride<br/><b>Sponsors</b>: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Office of Research on Women's Health (ORWH); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)<br/><b>Recruiting</b> - verified June 2010
Reducing Dietary Energy Density by Incorporating Vegetables in Order to Decrease Energy Intake
<b>Condition</b>: Obesity<br/><b>Intervention</b>: Other: Incorporating vegetables into the diet to reduce energy density<br/><b>Sponsors</b>: Penn State University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)<br/><b>Active, not recruiting</b> - verified July 2010
|
|
Useful Drugs For Treatment Of Obesity By Hayden Eck What is Obesity? Obesity is largely considered a lifestyle disease that has become the second leading cause of preventable deaths. This disease needs proper medical attention. Severe obesity is threatening and can affect lifespan of a person. It can easily lead to development of life-threatening complications such as high blood pressure and type 2 diabetes. Reasons of Obesity Environmental factors play an important role in spreading this medical condition. You can also cite reasons for obesity such as increasing dependence on modern equipment such as elevators and escalators. People spend long hours in front of their computer or watching television. Consumption of high calorie food is also one of the reasons that set the ground for development of obesity. List of Popular Drugs for Obesity Treatment You can treat obesity with the help of two accepted methods. One is drug therapy and the other is surgery. The surgical method for treatment of obesity is a quicker method but it also contains risks In addition, surgeries are too expensive and not everyone can afford it. People generally prefer drug therapy as this method does not contain any possibility of cuts or scars in the body. The most popular drugs that you can choose for treating obesity include Acomplia and Xenical. What is Acomplia? It is an anti-obesity drug manufactured by a pharmaceutical company named Sanofi-Aventis. Acomplia is first in the class of therapeutic drugs called Cannabinoid-1 Receptor Blockers (CB1) that hit the market. You can buy Acomplia only after obtaining prescription from a medical doctor. Ingredients of Acomplia The main ingredient of Acomplia is rimonabant and it works by selectively blocking CB1 receptors in the brain.
Author:
Bender, David A.
Page:
159-160
]]>
Author:
Dardevet, D. 1; Moore, M. C. 2; Remond, D. 1; Everett-Grueter, C. A. 2; Cherrington, A. D. 2,*
Page:
161-173
]]>
Author:
Brigelius-Flohe, Regina
Page:
174-186
]]>
Author:
Clavel, Thomas 1,2; Dore, Joel 2; Blaut, Michael 1,*
Page:
187-196
]]>
Author:
Saxton, John M.
Page:
197-215
]]>
Author:
Bosscher, D. *; Van Loo, J.; Franck, A.
Page:
216-226
]]>
Author:
Bannink, A. 1,*; Dijkstra, J. 2; Koopmans, S.-J. 1; Mroz, Z. 1
Page:
227-253
]]>
Author:
Guilloteau, P. 1,*; Le Meuth-Metzinger, V. 2; Morisset, J. 3; Zabielski, R. 4
Page:
254-283
]]>
Author:
Griffiths, Helen R. 1,*; Grant, Melissa M. 2
Page:
284-293
]]>
These receptors are responsible for glucose and lipid (or fat) metabolism in the body. Acomplia helps switch off brain circuits that make you feel hungry.
Benefits of Acomplia
Manufacturer of Acomplia claims that intake of Acomplia pills can prevent the risk of cardiovascular diseases in users. Another benefit is that it reduces large waist circumference such as 102cm in men and 88cm in women. The patients who are obese and suffer from type 2 or abnormal levels of fat in the blood can derive major benefits from Acomplia.
What is Xenical?
This oral prescription pill is very useful for those who are too obese. It can reduce about 50% of more body fat than you lose by dieting alone. You need to complement this medication with proper food habits and regular exercise.
Ingredients of Xenical
Orlistat is the main ingredient in Xenical that works to reduce fat absorbing ability of body. It does not affect your diet. You should consult a doctor for proper dosage of Xenical. However, you can take it in strengths of 60mg capsules three times a day with meals for positive results.
Benefits of Xenical
Xenical medication helps reduce blood pressure levels in the body. It also reduces triglycerides and decreases body fat. Xenical also reduces your chances of developing type 2 diabetes.
Who can take Acomplia and Xenical?
You can take Acomplia along with proper diet and exercise to treat your obesity problem. You can also take it if you suffer from medical conditions such as type 2 and abnormal levels of fat in the blood.
Doctor can prescribe Xenical to you if your BMI is greater than or equal to 30 kg/m2 or 27 kg/m2 and suffer from other risk factors such as hypertension, or increased serum cholesterol.
Availability of Acomplia and Xenical
Both Acomplia and Xenical are prescription pills and you can buy these pills online. This method is quite simple and proves to be an easy option for you. All you need to do is locate some genuine and reliable websites that sell these anti-obesity drugs. You will find an easy guide once you browse through these websites.Webmaster associated with online pharmacy "AtlanticDrug.com" this site provides various information on Acomplia Rimonabant and Xenical Orlistat and also helps people in curing Obesity, resources are available on site AtlanticDrugs.com.
Here are some more diabetes articles...
Manage Your Cholesterol With Natural Vitamin Supplements.
By ArticleTrader
The American Heart Association (AHA) has done a great job discovering what cholesterol does and how it affects our health. We know that high cholesterol can cause heart disease and stroke, and by Read more...
|
Infectious And Non-infectious Causes Of Sinus Infections - Part Two
By Groshan Fabiola
The gastro esophageal reflux disease with acid turns in the esophagus is being associated with many cases of respiratory diseases in children but also in some cases of chronic sinusitis in adults. In Read more...
|
|
|
|
Resources |
Obesity Is Not The Fault Of Individuals - Know About Obesity And It‘s Medicine Acomplia.
By Rythm Desai
A new report published today supported by the UK government has revealed that individuals should not be held responsible for obesity problems. The news comes just days after the UK health secretary Read more...
|
|
|
